Literature DB >> 28358122

Differentiation of Pancreatic Cyst Types by Analysis of Rheological Behavior of Pancreatic Cyst Fluid.

Iyad Khamaysi1,2, Aiman Abu Ammar3, Gleb Vasilyev3, Arkadii Arinstein3, Yehuda Chowers1,2, Eyal Zussman3.   

Abstract

Differentiation between mucinous and non-mucinous pancreatic cysts is exceedingly important and challenging, particularly as the former bears malignant transformation potential. Pancreatic cyst fluid (PCF)-based diagnostics, including analyses of biochemical markers, as well as cytology, has shown inadequate accuracy. Herein, a preliminary single-center study of 22 PCF samples, collected by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), assessed the rheological behavior of PCF and its correlation with lesion type. The dependence of PCF shear viscosity on shear rate was found to follow a power law and could be fitted using Ostwald-de Waele model. Three types of flow curves were identified, where two types correlated with non-mucinous cysts, differing by their power law exponent, and the third type corresponding to mucinous cysts. Viscosity measured at a high shear rate was shown to serve as an accurate and independent marker distinguishing between mucinous and non-mucinous cysts, with an optimal cutoff value of ηc = 1.3 cP The accuracy of this novel technique proved superior to string-sign, cytology, carcinoembryonic antigen, and amylase assessments. Moreover, the combined predictive value of ηc and patient age provided for sensitivity and specificity of 100% and 95.5%, respectively. This simple and rapid diagnostic tool can be immediately implemented after EUS-FNA sampling.

Entities:  

Mesh:

Year:  2017        PMID: 28358122      PMCID: PMC5372360          DOI: 10.1038/srep45589

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Pancreatic cancer is the fourth leading cause of cancer deaths among men and women, accounting for 6% of all cancer-related deaths, with a collective median survival time of 4–6 months. Pancreatic cancer is difficult to diagnose in its early stages; at the time of diagnosis, 52% of patients have distant metastases and 26% present regional spread1. Cystic lesions of the pancreas, a harbinger of pancreatic cancer, remain one of the most challenging lesions to diagnose and treat. Such cysts are frequently incidentally detected in patients undergoing abdominal imaging [i.e., computed tomography (CT) or magnetic resonance imaging (MRI)] for other indications. The most commonly occurring pancreatic cysts lack malignant potential, including retention (simple) cysts, pseudocysts and serous cystadenomas (Fig. 1). Less common are mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) that have malignant potential and require surgical intervention. Some lesions, such as serous cystadenomas or pseudocysts, can be monitored, while others, such as cystic pancreatic adenocarcinomas and neuroendocrine tumors, must be promptly resected. Still more complex is the treatment of MCN, which, depending on a variety of characteristics, may or may not need to be resected234. Owing to the possibility of malignancy, its immediate impact on patient survival and oftentimes urgency of active intervention, there is a need to differentiate between benign and malignant pancreatic lesions. At the same time, unnecessary pancreatic operations bring with them a high mortality rate, which can be avoided by accurate diagnosis.
Figure 1

Classification of pancreatic cysts.

Imaging plays a vital role in both detection and characterization of pancreatic cyst lesions. An example of representative CT, MRI, and endoscopic ultrasound (EUS) images of pancreatic body cysts, are presented in Fig. 2. CT, MRI, and EUS can provide a clear indication of cyst location and morphology, but still suffer from inadequate diagnostic accuracy5. The endoscopic ultrasound-guided fine needle aspiration method (EUS-FNA) allows for aspiration of pancreatic cyst fluid (PCF) from suspected lesions56, which, upon analysis, can enhance diagnostic sensitivity and can be a helpful tool in distinguishing between benign and malignant pancreatic lesions7.
Figure 2

Pancreatic body cysts as detected by CT (A,B), MRI (C,D), EUS (E) and EUS-FNA (F). Arrows indicate the location of the pancreatic cyst.

PCF analysis for cytology and markers has been widely used for the differential diagnosis of pancreatic cysts89101112. Among them, the carcinoembryonic antigen (CEA) marker demonstrates the highest diagnostic accuracy in discriminating between mucinous cyst (MC) and non-mucinous cyst (NMC)131415, and in a large multicenter study16, demonstrated 77% specificity and 61% sensitivity at a cutoff value of 192 ng/mL cyst fluid CEA. However, CEA levels cannot accurately differentiate between pancreatic cyst types, and therefore is not used as a stand-alone diagnostic measure17. Cyst fluid amylase is a useful marker, as it is elevated in pseudocysts and cysts, such as IPMNs, that communicate with the pancreatic duct18. The rheological characteristics of the PCF can serve as an indirect measure of the concentration and structural properties of cyst fluid mucin, glycoproteins and DNA content19. A common method for the characterization of PCF is the ‘string-sign’ method, which measures PCF properties under rapid extension2. The method involves placing a sample of the aspirated fluid between the thumb and index finger and quickly separating them to measure the distance between the fingers before the sample breaks. It was reported that a higher break length of the cyst fluid correlates with a lower likelihood of a benign cyst, while a 1 mm increase in break length corresponds to a 116% increase in the likelihood of a mucinous cyst2. This feature may be the result of loss of elasticity in the fluid, or disentanglement of the protein network as a result of the capillary pressure in the thread, which tends towards very high values20. However, the method lacks a theoretical framework for predicting the viscoelastic nature of the cyst fluid, which can typically be characterized by the viscous and elastic response of a fluid under deformation2122. The viscous component relates to energy dissipated during flow, while the elastic component relates to energy stored during flow, both of which can be altered by variations in the PCF structure or composition. As an example, it was demonstrated that introduction of a small amount of protein (e.g., 0.01% w/w) into a Newtonian medium can lead to a drastic change its viscous response, transforming to yield behavior, which is typical for structured liquids23. Also, increasing the concentration of mucins in gallbladder bile fluid resulted in increased viscosity24. An additional form of analysis performed on cyst fluids involves measurement of the relative viscosity of the aspirate under shear flow through a capillary. The relative viscosity of fluid from benign cysts has been shown to be significantly lower than of fluids derived from mucinous and malignant cysts. The relative viscosity of cyst fluids demonstrated high values (>1.63) in 89% of mucinous tumors and low values in all tested fluids from pseudocysts and serous cystadenomas. Relative viscosity values below the 1.63 cut-off accurately predicted non-mucinous cysts and strongly suggested that the cyst was benign15. In a more recent study, it was shown that relative viscosity was significantly higher for MCNs compared to pseudocysts and serous cystic tumors (1.8–1.9 and 1.2–1.3, respectively)25. Thus, the viscosity of the cyst fluids appears to be strongly affected by the nature and relative ratios of the dissolved constituents, which differ between cyst types. The aim of the present study was to assess the utility of the rheological properties of pancreatic cyst fluid, as compared with cytological and biochemical analyses, in differentiating between pancreatic cyst types. The proposed approach is based on measurement of the shear viscosity of PCF and construction of a flow curve of the cyst fluid. Furthermore, it was shown that the combination of several markers, such as viscosity and age of patient, increased diagnostic sensitivity, specificity and accuracy, and bear prognostic value and factors to integrate in clinical decision-making guidelines.

Results

A total of 22 patients (mean age: 57.1 years [SD = 16.2], Table S1) underwent EUS-FNA; cyst fluids were sent for cytological, biochemical and rheological assessments. Cysts were classified as MC (mucinous cystadenoma, mucinous adenocarcinoma, IPMN) or NMC (serous cystadenoma, pseudocyst), based on surgical and/or clinical findings (presentation, follow-up, imaging and fluid analyses). The baseline patient characteristics, the diameter of the cyst, the location of the cyst in the pancreas, the level of tumor markers (CEA, amylase), results of the cytological examination, string sign and rheological measurements are presented in Table 1. Overall, 10 lesions (45.45%) were classified as MC, while 12 (54.54%) were classified as NMC, 5 of which (22.72%) were considered pseudocysts.
Table 1

Patient demographics and cyst characteristics.

Sample no.SexAge (y)Cyst dia. (mm)LocationCEA (ng/mL)Amylase (U/L)CytologyString signFlow curve typeFinal diagnosisCyst type
1Female4628Tail53122Negative0ISCNMC
2Male4722Body49.861Negative0IIISimpleNMC
3Female7525Body977629Positive1IIIPMNMC
4Female6822Body286.42896Negative0IIPMNMC
5Female5370Head2480867Positive1IIICancerMC
6Female5250Head0.167483Negative0ISCNMC
7Female2135Body0.164Negative1IISCNMC
8Male2130Head0.168Negative1IISCNMC
9Female5933Body0.1111Negative1IISCNMC
10Male7735Head23247060Negative1IIIIPMNMC
11Female3935Body22.2107580Negative0IIPCPC
12Male5326Body5.1282240Negative0IIPCPC
13Male6220Body32.827018Positive1IIIPMNMC
14Female5845Body2950162Negative0IIPCPC
15Male7730Body2.4118000Negative0IIIIPMNMC
16Male5335Body12.4465Negative0IISCNMC
17Female7070Tail1.260Negative0IIICancerMC
18Male5570Tail12823833Negative0IIPCPC
19Male5860Body18184000Negative1IIPCPC
20Male5640Body3271491Negative0IIICancerMC
21Female7880Tail10397033Positive0IIICancerMC
22Male7830Body7.6737000Negative1IIIIPMNMC

SC - serous cystadenomas; MC - mucinous cyst; NMC - non-mucinous cyst; PC - pseudocyst; IPMN - intraductal papillary mucinous neoplasm. String sign = ‘1’, when there is a high likelihood of a mucinous cyst. Cytology was considered positive if the cytopathologist report included malignant (or suspicious) cells; otherwise, it was considered negative.

For the rheological assessment, the extracted fluids were evaluated by both string-sign test and viscosity measurements. Flow curves were drawn up, with the viscosity, η, plotted against the shear rate, γ. In order to describe PCF behavior across the range of shear rates, a power law model was employed: where, K and n are the fitting parameters and η is treated as infinite viscosity. This power law, also known as the Ostwald–de Waele power law, is typically used to describe the behavior of non-Newtonian fluids. For example, if n < 1, the power law predicts that the apparent viscosity will decrease indefinitely with increasing shear rate. Fitting of the flow curves of the PCFs using Eq. 1, and clustering the fitting parameters (K, n and η) (Table 2), resulted in three types of flow curves (I, II, III) (Fig. 3). More detailed information, including flow curves, as well as the values of K, n and η for each of the tested PCF samples, is provided in the Supplementary data (Figure S1 and Table S2, respectively). At infinite shear rate, , type II and I flow curves demonstrated nearly similar low viscosity, η = 1.01 cP and η = 1.04 cP respectively, while a significantly higher infinite viscosity, η = 1.55 cP, was found for type III. In addition, at low shear rates, the viscosity of type III samples was one order of magnitude higher than the type I samples, and double that of the type II samples, indicating an entirely different fluid micro-structure. Based on the diagnostic results determined using clinical findings (Table 1), we can induce that NMCs display types I + II rheological behavior, while MCs display type III flow curves. Statistical analysis of the flow curve classifications (Table 3) demonstrated a significant difference in the rheological behavior of MCs (flow curve III) versus NMCs (flow curves I + II) (p < 0.0001). It is evident in the inset of Fig. 3, that confidence intervals for flow curve of type III and that of the types I + II do not overlap, and the difference between the minimal value of infinite viscosity of group III and the maximum value of η of types I + II, marked by dash lines, covers the range of η = 1.15−1.30 cP. These findings indicate that η is a potentially suitable marker for distinguishing between MC and NMC. However, infinite viscosity is an extrapolated value, thus, it was decided to measure the viscosity, η at high shear rates (i.e., ); they proved similar to those determined at.
Table 2

Averaged values of the model parameters for the PCF samples.

Flow curve type #η (cP)Kn
I1.04 ± 0.10<10−5≈0
II1.01 ± 0.130.025 ± 0.018−0.79 ± 0.25
III1.55 ± 0.260.026 ± 0.019−0.62 ± 0.17
Figure 3

Representative types of I, II and III flow curves.

The graph inset shows the values of infinite viscosity, η, depicting the difference between the minimal value of type III and the maximum value of types I and II.

Table 3

Mean values of predictive factors in PCF sample subgroups.

 Flow curveNumberMean ± SDMedian (range)P value
Age (60 y) 22 (total)57.1 ± 16.257 (21–78) 
I355.3 ± 11.452 (46–68) 
II1150.4 ± 16.855 (21–75) 
I + II1451.4 ± 15.554 (21–75)0.020
III867 ± 12.973.5 (47–78)
Amylase (U/L) 22 (total)72216 ± 1655181694 (22–737000) 
I323467 ± 381462896 (22–67483) 
II1159597 ± 944883833 (29–282240) 
I + II1451855 ± 856053365 (22–282240)0.297
III8107847 ± 257487279 (33–737000)
CEA (ng/mL) 22 (total)6656 ± 2242926 (0–103970) 
I3273 ± 266286 (0–531) 
II111016 ± 293018 (0–9776) 
I + II14857 ± 259120 (0–9776)0.014
III816804 ± 362181187 (1–103970)
Cyst Diameter (mm) 22 (total)40.5 ± 18.135 (20–80) 
I333.33 ± 14.7428 (22–50) 
II1137.64 ± 15.1935 (20–70) 
I + II1436.71 ± 14.6434 (20–70)0.294
III847.13 ± 22.537.5 (22–80)
Viscosity, ηc (cP) 22 (total)1.32 ± 0.331.19 (0.97–2.08) 
I31.04 ± 0.10.99 (0.97–1.15) 
II111.13 ± 0.081.15 (1.01–1.24) 
I + II141.11 ± 0.091.15 (0.97–1.24)<0.0001
III81.69 ± 0.261.64 (1.41–2.08)

η-Viscosity measured at strain rate

For the purpose of comparing between predictive factors in their diagnostic capacity to differentiate between mucinous and non-mucinous PCFs, the statistical significance of mean values measured for flow curve types I + II versus III are presented in Table 3. It can be seen that CEA levels were significantly lower among NMCs as compared to MCs (p < 0.014). No significant difference in amylase levels was observed between MC versus NMC, although they increased significantly in pseudocysts, compared to other NMCs (Table S1). It is important to mention that patients with MCs were older than those with NMCs (69.4 and 46.8 years old, respectively). Moreover, there was no substantial difference in cyst diameters between MC and NMC lesions. However, mean viscosity η values were significantly different between type I and II lesions versus type III lesions (p < 0.0001). Receiver operator curve analysis of the cyst fluid viscosity, η, established that the optimal cutoff value for differentiating between MC (flow curve III) versus NMC (flow curve I and II) cysts was 1.3 cP (Fig. 4A), with area under the curve (AUC) of 0.817 (Fig. 4B). The sensitivity, specificity and accuracy of cystic fluid CEA, amylase, cytology, string sign, age, viscosity η and various combinations of these criteria used to predict whether the cysts were MC or NMC, are presented in Table 4. Using the optimal cutoff value, the sensitivity, specificity, and accuracy of cyst fluid viscosity η - based diagnosis of MC versus NMC were 70%, 91.7%, and 81.8%, respectively. In comparison, string-sign analysis showed a sensitivity, specificity and accuracy of 50%, 66.7%, and 59.1%, respectively. The overall accuracy of the viscosity-based technique (81.8%) was greater than that of CEA (72.7%), amylase (50%), cytology (72.7%) and string-sign (59.1%). When considering cyst fluid viscosity, η jointly with patient age, the sensitivity and the accuracy increased to 100% and 95.5%, respectively, but the specificity remained 91.7%.
Figure 4

(A) Receiver operator characteristic (ROC) curve evaluating the performance of cyst fluid viscosity, η, measured at strain rate (B) ROC analysis of age, CEA and η in differentiation between MCN vs. NMC.

Table 4

Statistical parameters of various diagnostic approaches for differentiating between MC versus NMC lesions.

MethodSensitivitySpecificityPPVNPVAccuracyP value
Age0.8001.001.000.8570.9090.000
String-Sign0.5000.6670.5560.6150.5910.666
CEA (192 ng/mL)0.6000.8330.7500.7140.7270.074
CEA (1000 ng/mL)0.5000.9170.8330.6880.7270.056
Amylase (1200 U/L)0.5000.5000.4550.5450.5001.000
PC/NMC- Amylase (1200 U/L)1.000.8571.000.8570.9170.015
Cytology0.4001.001.000.6670.7270.029
Viscosity, ηc0.7000.9170.8750.7860.8180.006
Combinations
CEA (192 ng/mL) + Amylase (1200 U/L)0.2000.9170.6670.5790.5910.571
CEA (192 ng/mL) + Amylase (1200 U/L) + string sign0.6000.8330.7500.7140.7270.074
string sign + CEA (192 ng/mL)0.7000.5830.5830.7000.6360.231
Viscosity, ηc + CEA (192 ng/mL)0.9000.7500.9000.9000.8180.004
Viscosity, ηc + Age (I + II & < 60)1.000.9171.001.000.9550.000
Viscosity, ηc + CEA (1000 ng/mL)0.8000.8330.8000.8330.8180.008

PPV positive predictive value, NPV negative predictive value.

η - Viscosity measured at strain rate

Discussion

When focusing on the change in viscosity, η as a function of shear rate, three types of flow curves were easily distinguished (Fig. 3). For type I fluids, the viscosity was constant at all shear rates, close to Newtonian behavior, n∼0, where the absolute values of the viscosity were close to viscosity of water at room temperature. This behavior is typical of low molecular weight fluids as well as for diluted polymer solutions or dispersions. Types II and III PCF samples demonstrated yield behavior n < 0, i.e., strong shear thinning at low shear rates. This kind of behavior is typically associated with the presence of a structure in the fluid (e.g., formed by proteins), which is destroyed upon application of the shear field, resulting in a sharp drop in viscosity. The viscosity tends to level off, approaching a constant value (infinite viscosity, η) as the shear rate increases. The lowest constant viscosity reflects the properties of the fluids when its structure has been completely destroyed (disentangled macromolecules). Such behavior is expected of a multicomponent fluid, such as PCF, whose bulk is comprised of mucins, characterized by high molecular weight, heavily glycosylated proteins4. It has been established that MCs show elevated concentration of mucins in comparison with NMCs25, corresponding to flow type III. Indeed, the present analysis classified the rheological behavior of PCFs from malignant or potentially malignant lesions as type III, which was later corroborated by surgical pathology. In addition, no correlation was observed between the diagnostic capacity of the viscosity, η, measurements to that of the CEA and amylase. For instance, viscosity evaluations, as well as pathology, categorized PCF samples nos 5, 15 and 21 as MC, while CEA and amylase levels of samples nos 15 and 21 differed from sample no. 5 by four orders of magnitude (Table S3). Moreover, PCF sample no. 1 displayed a high CEA level of 531 ng/ml and was therefore considered a MC, yet, surgical pathology classified this tumor as serous (Table S3) and the rheological behavior of this sample matched that of flow curve type I. These results underscore the wide variability and suboptimal accuracy of CEA-based diagnosis, as well as the need for alternative and more precise diagnostic tools17. The rheological properties of PCF are strongly influenced by mucin content, which is commonly manually evaluated, by means of the subjective and variable string-sign method. In their examination of the value of string-sign determination in differentiating between pancreatic cyst types, Leung et al. found that increased cyst fluid viscosity was associated with malignant or potentially malignant cysts2. In a recent study, Bick et al.26 evaluated the utility of the string-sign approach in the diagnosis of mucinous pancreatic cysts; high specificity, as well as improved diagnostic accuracy of the method was mentioned. The authors considered the test results positive when the string was at least 1 cm long and remained stable for at least 1 second before disruption, by subjective judgment. Our analysis of the flow curves of the cyst fluids, exhibited better performance than the string-sign method, as manifested by sensitivity, specify, PPV, NPV and accuracy values (Table 4). Moreover, when used as a sole parameter, measurement of viscosity, η, at a high shear rate (20001/s, was superior to other methods, with an overall accuracy of approximately 81.8%. Furthermore, when combined with age, the method provided for impressive sensitivity and accuracy of 100% and 95.5%, respectively. Utilization of this approach provides for robust results, with less variation compared to the string-sign method, due to the use of a rheometer instead of subjective assessments.

Conclusions

Rheological characterization of pancreatic cyst fluid proved a promising and simple means of identifying potential pancreatic malignancies. Three distinct flow curves of the rheological behavior of PCFs were identified, with types I and II hypothesized to correlate with non-mucinous cysts, and type III with mucinous cysts. The cutoff value of viscosity, η, measured at strain rate 20001/s, can serve as an independent marker to distinguish between mucinous and non-mucinous cysts. It was found that η > 1.3 cP characterizes MCs, whereas η > 1.3 cP is typical for NMCs. This simple and rapid diagnostic tool can be immediately implemented after EUS-FNA sampling, and provides for a low variability rate compared to the commonly used, subjective string sign technique. Although the findings are promising, they must be further confirmed in a large-scale study.

Methods

Ethics statement

All experimental protocols were approved by the Rambam Medical Center Ethics Committee (0064-14-RMB, 2nd February 2014) and were carried out in accordance with the approved guidelines. All patients signed an informed consent form prior to the EUS-FNA or blood sampling.

Study design and patients

The cohort consisted of 22 (11 males and 11 females) patients with a suspicious pancreatic cystic lesion, detected by cross-sectional imaging (CT and/or MRI scan) and consequentially referred for an EUS-FNA. Pancreatic cyst fluid samples were collected for cytological and biochemical analysis and patients were followed-up. In addition to routine cyst fluid analysis (biochemical, cytological and string-sign viscosity assessment), rheological measurement were performed (see below). Pancreatic cysts were classified as mucinous (mucinous cystadenoma, mucinous adenocarcinoma, IPMN) or non-mucinous (serous cystadenoma, pseudocyst), based on surgical and/or clinical findings (presentation, follow-up, imaging and fluid analysis).

Cyst fluid collection and evaluation

A curvilinear array echoendoscope (Pentax Inc. EG-3630U, Montvale, NJ) was used to insert a 22-gauge needle (Cook Medical Inc. Bloomington, IN, Boston expect or Olympus Inc.), under ultrasound guidance, to aspirate the cyst fluid. Cyst fluid characteristics were recorded. The levels of biochemical markers of cyst fluid CEA and amylase were measured using commercial solid-phase double- antibody (Abbott Laboratories, Ill). Specimens were cytopathologically analyzed for the presence of mucinous epithelium, extent of cytologic atypia and presence of malignant cells. A cellblock was prepared for further immunohistological staining, as described previously27. The string-sign was determined at aspiration, by the endosonographer, as described previously2. In brief, a drop of fluid was placed between the thumb and index finger and the maximum length of stretch before disruption of the mucous string, was measured and recorded.

Rheological measurements

PCF samples were stored at 4 °C, incubated at room temperature for one hour prior to measurements, and vortexed for 30 sec just before testing, to ensure homogenization. Use of a rotational viscometer supports simulation of true rheological conditions (the stepping change of either the shear stress or the shear rate is programmed but the parameter remains constant during each step). The viscosity of the PCF samples was measured with a DHR-2 Rheometer (TA Instruments, USA) at 25 °C. The preferred geometry was cone-and-plate, with a cone diameter of 40 mm and a surface-plate angle of 1°. The rheometer was operated in shear rate control mode. Several time sweep tests at different constant shear rates (5–2000 1/s) were performed. The measured steady-state shear viscosity values (when the viscosity was constant in time) were used to construct flow curves of the fluids. Measurements were repeated 1–4 times for each sample, depending on the amount of fluid aspirated. The flow curves (viscosity versus shear stress or shear rate), characterizing the viscous response of the fluid under the shear field over a wide range of conditions, were then graphed.

Data Analysis

Statistical analysis was performed using the nonparametric Mann-Whitney U-test, Pearson’s chi-squared test and receiver operating characteristic (ROC) curve. Cutoff points of age, CEA and viscosity were evaluated by ROC curve analysis and Youden’s statistics. Sensitivity, specificity and accuracy were calculated. A p value < 0.05 was considered significant. All analyses were performed using SPSS 21.0 (IBM Corp., Armonk, NY, USA).

Additional Information

How to cite this article: Khamaysi, I. et al. Differentiation of Pancreatic Cyst Types by Analysis of Rheological Behavior of Pancreatic Cyst Fluid. Sci. Rep. 7, 45589; doi: 10.1038/srep45589 (2017). Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
  22 in total

Review 1.  Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis.

Authors:  Laurens A van der Waaij; Hendrik M van Dullemen; Robert J Porte
Journal:  Gastrointest Endosc       Date:  2005-09       Impact factor: 9.427

2.  The mistletoe and cyst-fluid analysis: a sticky insight.

Authors:  William R Brugge
Journal:  Gastrointest Endosc       Date:  2006-11       Impact factor: 9.427

Review 3.  Pancreatic cyst fluid analysis--a review.

Authors:  Manoop S Bhutani; Vikas Gupta; Sushovan Guha; Dan Ionuţ Gheonea; Adrian Saftoiu
Journal:  J Gastrointestin Liver Dis       Date:  2011-06       Impact factor: 2.008

Review 4.  Management of mucinous cystic neoplasms of the pancreas.

Authors:  Mario Testini; Angela Gurrado; Germana Lissidini; Pietro Venezia; Luigi Greco; Giuseppe Piccinni
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

5.  EUS and EUS-FNA diagnosis of suspected pancreatic cystic neoplasms: Is the sum of the parts greater than the CEA?

Authors:  K W Oppong; M F Dawwas; R M Charnley; V Wadehra; K Elamin; S White; M Nayar
Journal:  Pancreatology       Date:  2015-08-21       Impact factor: 3.996

6.  Endoscopic ultrasound-guided fine needle aspiration and cyst fluid analysis for pancreatic cysts.

Authors:  Siriboon Attasaranya; Shireen Pais; Julia LeBlanc; Lee McHenry; Stuart Sherman; John M DeWitt
Journal:  JOP       Date:  2007-09-07

7.  Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.

Authors:  William R Brugge; Kent Lewandrowski; Elizabeth Lee-Lewandrowski; Barbara A Centeno; Tara Szydlo; Susan Regan; Carlos Fernandez del Castillo; Andrew L Warshaw
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

Review 8.  Diagnosis and management of cystic pancreatic lesions.

Authors:  Dushyant V Sahani; Avinash Kambadakone; Michael Macari; Noaki Takahashi; Suresh Chari; Carlos Fernandez-del Castillo
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm.

Authors:  Christopher J DiMaio; Frances Weis-Garcia; Emilia Bagiella; Laura H Tang; Peter J Allen
Journal:  Gastrointest Endosc       Date:  2015-09-25       Impact factor: 9.427

10.  Role of endoscopic ultrasound-guided fine-needle aspiration cytology, viscosity, and carcinoembryonic antigen in pancreatic cyst fluid.

Authors:  Samer Alkaade; Elie Chahla; Michael Levy
Journal:  Endosc Ultrasound       Date:  2015 Oct-Dec       Impact factor: 5.628

View more
  5 in total

Review 1.  Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Authors:  Aatur D Singhi; Eugene J Koay; Suresh T Chari; Anirban Maitra
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

2.  Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts.

Authors:  Vallabh Suresh; Kaleb Byers; Ummadisetti Chinna Rajesh; Francesco Caiazza; Gina Zhu; Charles S Craik; Kimberly Kirkwood; Vincent Jo Davisson; Daniel A Sheik
Journal:  Diagnostics (Basel)       Date:  2022-05-28

3.  An international study of interobserver variability of "string sign" of pancreatic cysts among experienced endosonographers.

Authors:  Seifeldin Hakim; Emmanuel Coronel; Graciela M Nogueras González; Philip S Ge; Suresh T Chari; Nirav Thosani; Srinivas Ramireddy; Ricardo Badillo; Tomas DaVee; Marc F Catalano; Robert J Sealock; Sreeram Parupudi; Lyndon V Hernandez; Virendra Joshi; Atsushi Irisawa; Surinder Rana; Sundeep Lakhtakia; Peter Vilmann; Adrian Saftoiu; Siyu Sun; Marc Giovannini; Matthew H Katz; Michael P Kim; Manoop S Bhutani
Journal:  Endosc Ultrasound       Date:  2021 Jan-Feb       Impact factor: 5.628

4.  String sign: Can we make it more scientific?

Authors:  Iyad Khamaysi; Gadeer A'li Taha; Efad Weishahi; Eyal Zussman
Journal:  Endosc Ultrasound       Date:  2022 Jan-Feb       Impact factor: 5.628

5.  Pancreatic cyst dilemma: Between physical and biochemical markers.

Authors:  Iyad Khamaysi; Eyal Zussman
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.